Updates are available Correction dated 2021-04-23

Article History

Accepted: 28 February 2021

First Online: 31 March 2021

Change Date: 23 April 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40266-021-00860-8

Declarations

:

: This study was funded by Salix Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor^® from Progenics Pharmaceuticals, Inc., New York, NY, USA, a wholly owned subsidiary of Lantheus Holdings, Inc., North Billerica, MA, USA.

: Solomon S. Liao has no disclosures to report; Neal E. Slatkin is an employee and shareholder of Salix Pharmaceuticals, a division of Bausch Health US, LLC; and Nancy Stambler is a full-time employee of Progenics Pharmaceuticals.

: Each study received local or central Institutional Review Board approval and followed good clinical practice and Declaration of Helsinki principles.

: Each study obtained pre-enrollment patient written informed consent.

: The datasets generated and/or analyzed during the current study are not publicly available at this time due to the proprietary nature of this information. Requests for additional information should be made to the corresponding author.

: Not applicable.

: All authors made substantial contributions to conception, design, and interpretation of the analysis; participated in revising the manuscript critically for important intellectual content; and provided final approval of the manuscript.